Biotech

Amgen takes BiTEs out of pipeline, dropping BCMA, PSMA assets

With a who’s who of drug developers going after BCMA, Amgen is stopping work on its bispecific contender for the multiple myeloma market.
Nick Paul Taylor Aug 5, 2022 7:50am

Neurocrine axes essential tremor program on phase 2 data

Aug 5, 2022 4:53am

AstraZeneca quietly works on its own off-the-shelf CAR-Ts

Aug 4, 2022 6:00am

Fierce Biotech Fundraising Tracker: F2G, Sironax and more

Aug 4, 2022 4:20pm

Talis Bio walks away from COVID test plans, cuts 35% of staff

Aug 5, 2022 11:33am

Merck responds to FDA letter for chronic cough med gefapixant

Aug 5, 2022 10:21am
CRO News

Crown Bioscience rejigs executive team, plans global expansion

Aug 2, 2022 8:57am

Clario joins workplace diversity, equity and inclusion movement

Aug 2, 2022 8:00am

Labcorp to splice off clinical development arm

Jul 28, 2022 10:45am

Velocity Clinical Research buys trial site in Germany

Jul 27, 2022 3:45pm